J
J. M. Goldman
Researcher at Imperial College London
Publications - 123
Citations - 5679
J. M. Goldman is an academic researcher from Imperial College London. The author has contributed to research in topics: Bone marrow & Myeloid leukemia. The author has an hindex of 42, co-authored 123 publications receiving 5611 citations. Previous affiliations of J. M. Goldman include Heidelberg University & Royal Free Hospital.
Papers
More filters
Journal ArticleDOI
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse
F. Van Rhee,F. Lin,Jonathan O. Cullis,Andrew Spencer,Nicholas C.P. Cross,Andrew Chase,B. Garicochea,Julie Bungey,J. Barrett,J. M. Goldman +9 more
TL;DR: Therapeutic intervention before the onset of hematologic relapse was associated with an increased likelihood of response and no marrow aplasia and it is confirmed that donor leukocyte transfusions are effective in the management of CML in relapse after BMT.
Journal Article
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.
TL;DR: A rapid and simple polymerase chain reaction (PCR) method is described that is capable of identifying any of the BCR-ABL transcripts that have yet been described in chronic myeloid or acute lymphoblastic leukaemia.
Journal ArticleDOI
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
Francesco Dazzi,Richard Szydlo,Charles Craddock,Nicholas C.P. Cross,Jaspal Kaeda,Andrew Chase,Eduardo Olavarria,F. Van Rhee,Edward Kanfer,J. F. Apperley,J. M. Goldman +10 more
TL;DR: The findings suggest that the incidence of GVHD associated with the EDR is low, not because the final cell dose is small, but because lymphocytes are administered over a considerable number of months.
Journal ArticleDOI
Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission
Andreas Hochhaus,Andreas Reiter,Andreas Reiter,Andreas Reiter,S. Saussele,S. Saussele,S. Saussele,A. Reichert,A. Reichert,A. Reichert,M. Emig,M. Emig,M. Emig,Jaspal Kaeda,Jaspal Kaeda,Jaspal Kaeda,Beate Schultheis,Beate Schultheis,Beate Schultheis,U. Berger,U. Berger,U. Berger,P. C. A. Shepherd,P. C. A. Shepherd,P. C. A. Shepherd,N. C. Allan,N. C. Allan,N. C. Allan,R. Hehlmann,R. Hehlmann,R. Hehlmann,J. M. Goldman,J. M. Goldman,J. M. Goldman,Nicholas C. P. Cross,Nicholas C. P. Cross,Nicholas C. P. Cross +36 more
TL;DR: The findings show that the level of residual disease falls with time in complete responders to IFN, but molecular evidence of disease is rarely if ever eliminated, and suggest that for patients who reach CR, IFN should be continued at least until relatively low levels of residual leukemia are achieved.
Journal ArticleDOI
The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia
TL;DR: If an ABL-BCR gene product is produced in CML cells, it may be relevant as a mechanism for deregulating the GTPase activating protein (GAP) function of BCR.